47 results on '"Owen, Andrew"'
Search Results
2. Small bowel resection for ischemia following transcatheter arterial embolization for bleeding jejunal diverticulum: an easily forgotten complication
3. Single‐dose immunisation with a multimerised SARS‐CoV‐2 receptor binding domain (RBD) induces an enhanced and protective response in mice
4. In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel
5. Ultrasound‐guided portal vein puncture during Transjugular Intrahepatic Portosystemic Shunt: Technique and experience of a quaternary liver transplant hospital
6. Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis
7. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development
8. Chasing COVID‐19 chemotherapeutics without putting the cart before the horse
9. Safety perspectives on presently considered drugs for the treatment of COVID‐19
10. Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
11. Influence of SLCO1B1 polymorphisms on lopinavir C trough in Serbian HIV/AIDS patients
12. Critical considerations for targeting colorectal liver metastases with nanotechnology
13. CYP2B6 *6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers
14. Vertebroplasty for acute painful osteoporotic vertebral compression fractures: An update
15. Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?
16. Development of Prodrug Approaches for Long‐Acting Nanoformulations of Emtricitabine‐Based Regimens
17. Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
18. Intracellular delivery of nano‐formulated antituberculosis drugs enhances bactericidal activity
19. In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line
20. Foreword
21. Towards a rational design of solid drug nanoparticles with optimised pharmacological properties
22. Foreword
23. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
24. Interdisciplinary nanomedicine publications through interdisciplinary peer-review
25. Special issue of BJP on Nanomedicine
26. Chemical modification of the 6'‐amino cyclopropyl of abacavir eliminates HLA‐B*57:01‐restricted CD8+ T‐cell activation without loss of antiviral activity
27. KHA-CARI Guideline: Vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts
28. Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
29. Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems
30. GROOVED WARE FEASTING IN YORKSHIRE: LATE NEOLITHIC ANIMAL CONSUMPTION AT RUDSTON WOLD
31. TOWARD GREENER DIALYSIS: A CASE STUDY TO ILLUSTRATE AND ENCOURAGE THE SALVAGE OF REJECT WATER
32. The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes
33. Intracellular ‘boosting’ of darunavir using known transport inhibitors in primary PBMC
34. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements
35. The implications of P-glycoprotein in HIV: friend or foe?
36. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver
37. Carbamazepine is not a substrate for P-glycoprotein
38. Diagnosis of heart failure in elderly patients in primary care
39. Experience of commencing Carvedilol in elderly patients with heart failure in a routine outpatient clinic
40. Diagnosis of heart failure in the elderly in primary care
41. Effect of initiation dose of Carvedilol on heart rate and blood pressure in elderly patients with heart failure
42. An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
43. Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice
44. An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2.
45. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
46. CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers.
47. The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.